MY-875 is a potent microtubulin polymerization inhibitor that competes at colchicine binding sites, exhibiting an IC50 value of 0.92 μM. It effectively suppresses microtubulin polymerization, exerting its inhibitory effect. Additionally, MY-875 exerts its biological impact by activating the Hippo pathway, inducing apoptosis, and displaying commendable anticancer activity [1].

MY-875 (0-80 μM, 48 h) exhibits significant anti-proliferative activity against cancer cells [1]. At concentrations of 1-10 μM, MY-875 inhibits microtubule protein polymerization with an IC50 of 0.92 μM, while also preventing the alkylation of β-tubulin and formation of EBI-β-tubulin adduct bands dosedependently [1]. MY-875 (0-45 nM, 48 h) induces the phosphorylation of MST (Ste20-like kinases) and LATS (large tumor suppressor kinases), leading to YAP (Yes-associated protein) degradation [1]. Additionally, MY-875 (0-45 nM, 24 h) significantly impairs cell colony-forming ability, induces G2/M phase arrest, and triggers apoptosis in a dose-dependent manner [1].

**Cell Proliferation Assay [1]**
- **Cell Line:** MGC-803, HCT-116, KYSE450, HGC-27, SGC-7901
- **Concentration:** 0-80 μM
- **Incubation Time:** 48 hours
- **Result:** Inhibited proliferation with IC50 values of 0.027, 0.055, 0.067, 0.033, and 0.025 μM respectively. Also showed strong inhibitory effects on other tumor cell lines (e.g., DU145, A549, MCF-7) with IC50 < 0.1 μM.

**Cell Cycle Analysis [1]**
- **Cell Line:** MGC-803, SGC-7901
- **Concentration:** 0-45 nM
- **Incubation Time:** 24 hours
- **Result:** Increased G2/M phase cell percentage from 19.38% to 76.97% in MGC-803 and from 7.04% to 80.89% in SGC-7901 at 45 nM.

**Apoptosis Analysis [1]**
- **Cell Line:** MGC-803, SGC-7901
- **Concentration:** 0-45 nM
- **Incubation Time:** 48 hours
- **Result:** Increased apoptotic cell percentage from 21.96% to 76.08% in MGC-803 and from 9.28% to 63.51% in SGC-7901 at 45 nM, while reducing expression of anti-apoptotic proteins c-IAP1, Bcl-xL, and Mcl-1.